364 related articles for article (PubMed ID: 19483156)
1. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease in cerebrospinal fluid at diagnosis: a more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia.
Biojone E; Queiróz Rde P; Valera ET; Odashima NS; Takayanagui OM; Viana MB; Tone LG; Scrideli CA
Leuk Lymphoma; 2012 Jan; 53(1):89-95. PubMed ID: 21774746
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
Li AH; Forestier E; Rosenquist R; Roos G
Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
[TBL] [Abstract][Full Text] [Related]
4. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.
Irving J; Jesson J; Virgo P; Case M; Minto L; Eyre L; Noel N; Johansson U; Macey M; Knotts L; Helliwell M; Davies P; Whitby L; Barnett D; Hancock J; Goulden N; Lawson S; ;
Haematologica; 2009 Jun; 94(6):870-4. PubMed ID: 19377076
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
6. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
8. Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA - 2009 protocol.
Rocha JMC; Xavier SG; Souza MEL; Murao M; de Oliveira BM
Pediatr Hematol Oncol; 2019 Aug; 36(5):287-301. PubMed ID: 31287348
[TBL] [Abstract][Full Text] [Related]
9. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.
Gaipa G; Cazzaniga G; Valsecchi MG; Panzer-Grümayer R; Buldini B; Silvestri D; Karawajew L; Maglia O; Ratei R; Benetello A; Sala S; Schumich A; Schrauder A; Villa T; Veltroni M; Ludwig WD; Conter V; Schrappe M; Biondi A; Dworzak MN; Basso G
Haematologica; 2012 Oct; 97(10):1582-93. PubMed ID: 22581001
[TBL] [Abstract][Full Text] [Related]
10. Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.
Dawidowska M; Jółkowska J; Szczepański T; Derwich K; Wachowiak J; Witt M
Arch Immunol Ther Exp (Warsz); 2008; 56(6):409-18. PubMed ID: 19043668
[TBL] [Abstract][Full Text] [Related]
11. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease.
Szczepański T; Langerak AW; Wolvers-Tettero IL; Ossenkoppele GJ; Verhoef G; Stul M; Petersen EJ; de Bruijn MA; van't Veer MB; van Dongen JJ
Leukemia; 1998 Jul; 12(7):1081-8. PubMed ID: 9665194
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
14. Use of simplified strategies to evaluate early treatment response in childhood acute lymphoblastic leukemia.
Scrideli CA; de Paula Queiróz R; Bernardes JE; Defavery R; Valera ET; Tone LG
Leuk Res; 2006 Aug; 30(8):1049-52. PubMed ID: 16406015
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
Kolenova A; Hikkel I; Ilencikova D; Hikkelova M; Sejnova D; Kaiserova E; Cizmar A; Puskacova J; Bubanska E; Oravkinova I; Gencik M
Neoplasma; 2010; 57(6):552-61. PubMed ID: 20845994
[TBL] [Abstract][Full Text] [Related]
16. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
17. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
van der Velden VH; Willemse MJ; van der Schoot CE; Hählen K; van Wering ER; van Dongen JJ
Leukemia; 2002 May; 16(5):928-36. PubMed ID: 11986956
[TBL] [Abstract][Full Text] [Related]
19. Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia.
Evans PA; Short MA; Owen RG; Jack AS; Forsyth PD; Shiach CR; Kinsey S; Morgan GJ
J Clin Oncol; 1998 Nov; 16(11):3616-27. PubMed ID: 9817283
[TBL] [Abstract][Full Text] [Related]
20. How I investigate minimal residual disease in acute lymphoblastic leukemia.
Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
